Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Serum Nesfatin-1, YKL-40 and PRP in Knee Osteoarthritis
NCT06254976Completed
- Sponsor
- Kayseri City Hospital
- Start
- Jun 2022
- Primary completion
- Jun 2023
- Modality
- Adipose-derived MSCs, Bone Marrow MSCs
- Countries
- 1
01
Overview
Open-label, single-arm trial of platelet-rich plasma in knee osteoarthritis (OA), sponsored by Kayseri City Hospital. Primary endpoints: Change in Serum YKL-40 levels at Day 28, Change in Serum nesfatin-1 levels at Day 28 and 4 more. Started Jun 2022; status: completed.
02
Drugs
platelet-rich plasma
03
Conditions
knee osteoarthritis (OA)
Beyond the preview
Go deeper on NCT06254976.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06254976.